Elevance Health Reports Better than Expected Results for Q1 2025

Elevance Health, Inc. (NYSE: ELV) has released its financial results for the first quarter of 2025, showcasing a significant increase in revenue and a slight uptick in earnings per share compared to the previous year. This article delves into the company’s current performance and future guidance.

Elevance Health Reports Better than Expected Results for Q1 2025

Elevance Health reported robust results for the first quarter of 2025, with operating revenue reaching $48.8 billion, a 15% increase from the previous year’s $42.3 billion. This growth was primarily fueled by higher premium yields in the Health Benefits segment, acquisitions completed in the past year, and an increase in Medicare Advantage and Individual ACA membership. The CarelonRx product revenue also contributed significantly to this increase, although there was some offset due to membership attrition in the Medicaid business.

The company’s adj. earnings per diluted share (EPS) of $11.97 exceeded the expected $11.08. This discrepancy can be attributed to various factors, including a higher benefit expense ratio of 86.4%, which rose by 80 basis points year-over-year. The increase in Medicaid medical cost trends played a significant role in this change, partially offset by out-of-period premium taxes.

Operating expenses showed improvement, with the operating expense ratio dropping to 10.9% from the previous year’s 11.6%. This was driven by expense leverage associated with revenue growth and ongoing cost management efforts. However, the adjusted operating margin for the Health Benefits segment decreased to 5.4% from 6.2% in the previous year, reflecting the challenges faced in managing medical costs within the Medicaid business.

Join our Telegram group and never miss a breaking digital asset story.

Elevance Health Reaffirms Full-Year 2025 Guidance

Looking ahead, Elevance Health has reaffirmed its full-year 2025 guidance, projecting adjusted EPS to range between $34.15 and $34.85. This outlook reflects the company’s confidence in its strategic initiatives and growth potential across its various segments. The management anticipates continued expansion in Medicare Advantage and Individual ACA membership, alongside further integration of recent acquisitions to bolster revenue streams.

In terms of capital deployment, Elevance Health returned $1.3 billion to shareholders during the first quarter through share repurchases and dividends. The company repurchased 2.2 million shares of its common stock for $880 million, with a weighted average price of $395.78 per share. Additionally, a quarterly dividend of $1.71 per share was distributed, amounting to a total cash distribution of $386 million.

Disclaimer: The author does not hold or have a position in any securities discussed in the article. All stock prices were quoted at the time of writing.